SGEN Jan 2024 200.000 call
| Previous close | 18.80 |
| Open | 16.00 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 200.00 |
| Expiry date | 2024-01-19 |
| Day's range | 15.82 - 18.80 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Business WireSeagen Stockholders Approve Acquisition by Pfizer
BOTHELL, Wash., May 30, 2023--Following a special meeting of its stockholders, Seagen Inc. (Nasdaq: SGEN) today announced that its stockholders voted to approve a proposal to adopt the previously announced merger agreement under which Pfizer will acquire Seagen for $229 per share in cash. More than 99% of the shares voted at the meeting, representing approximately 88% of the shares of Seagen common stock issued and outstanding as of the record date for the special meeting, were voted in favor of
Simply Wall St.We're Not Worried About Seagen's (NASDAQ:SGEN) Cash Burn
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Yahoo FinanceFTC sues to block Amgen's $28B acquisition of Horizon Therapeutics
The regulator said its decision "sends a clear signal to the market" about consolidation in the pharmaceutical market, though analysts expect the deal will still go through despite delays.
- Simply Wall St.
Seagen (NASDAQ:SGEN) shareholders have earned a 29% CAGR over the last five years
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...
- Simply Wall St.
Seagen Inc. (NASDAQ:SGEN) is largely controlled by institutional shareholders who own 65% of the company
Key Insights Significantly high institutional ownership implies Seagen's stock price is sensitive to their trading...
- Simply Wall St.
Estimating The Intrinsic Value Of Seagen Inc. (NASDAQ:SGEN)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Seagen fair value estimate is US$193 With US$200 share price...
- Simply Wall St.
16% of this Seagen Inc. (NASDAQ:SGEN) insider's holdings were sold in the last year
Looking at Seagen Inc.'s ( NASDAQ:SGEN ) insider transactions over the last year, we can see that insiders were net...
ZacksSeattle Genetics (SGEN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Seattle Genetics (SGEN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ZacksSeattle Genetics (SGEN) Reports Q1 Loss, Lags Revenue Estimates
Seattle Genetics (SGEN) delivered earnings and revenue surprises of -13.41% and 0.23%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireSeagen Reports First Quarter 2023 Financial Results
BOTHELL, Wash., April 27, 2023--Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the first quarter ended March 31, 2023. The Company also highlighted performance across its approved product portfolio, development accomplishments, and progress across its differentiated oncology pipeline of innovative ADCs and targeted therapies.
Business WireSeagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting
BOTHELL, Wash., April 26, 2023--Seagen Inc. (Nasdaq: SGEN) today announced the presentation of 17 abstracts at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023, in Chicago. Data will be presented across Seagen's portfolio of approved medicines and pipeline agents in a range of cancer types and in earlier lines of therapy.
ZacksRepligen (RGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Repligen (RGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
We're Interested To See How Seagen (NASDAQ:SGEN) Uses Its Cash Hoard To Grow
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- Simply Wall St.
Seagen Inc.'s (NASDAQ:SGEN) Business Is Trailing The Industry But Its Shares Aren't
You may think that with a price-to-sales (or "P/S") ratio of 19.6x Seagen Inc. ( NASDAQ:SGEN ) is a stock to avoid...
- Simply Wall St.
Investors in Seagen (NASDAQ:SGEN) have made a incredible return of 307% over the past five years
Long term investing can be life changing when you buy and hold the truly great businesses. While not every stock...
Business WireSeagen to Report First Quarter 2023 Financial Results on April 27, 2023
BOTHELL, Wash., April 07, 2023--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its first quarter 2023 financial results on Thursday, April 27, 2023.
Business WireFDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer
BOTHELL, Wash. & TOKYO, April 03, 2023--Seagen Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE:4503) today announced the U.S. Food and Drug Administration (FDA) has granted PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) accelerated approval in the U.S. as a combination therapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC) who are not eligible to receive cisplatin-containing chemotherapy. This indication is approved under ac
ZacksAmicus Therapeutics (FOLD) Down 14% Since Last Earnings Report: Can It Rebound?
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksWhy Is Iovance Biotherapeutics (IOVA) Down 9.2% Since Last Earnings Report?
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksAxsome (AXSM) Down 9.8% Since Last Earnings Report: Can It Rebound?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
A Seagen Inc. (NASDAQ:SGEN) insider lowered their holding by 16% earlier this year
Viewing insider transactions for Seagen Inc.'s ( NASDAQ:SGEN ) over the last year, we see that insiders were net...
ZacksWhy Is Repligen (RGEN) Down 11.4% Since Last Earnings Report?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksCRISPR Therapeutics AG (CRSP) Down 13.6% Since Last Earnings Report: Can It Rebound?
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Why Is Seattle Genetics (SGEN) Up 24.6% Since Last Earnings Report?
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Business WireSeagen to Present New Clinical and Preclinical Data From Broad Portfolio of Targeted Cancer Therapeutics at the 2023 AACR Annual Meeting
BOTHELL, Wash., March 14, 2023--Seagen Inc. (Nasdaq: SGEN) today announced the presentation of 17 abstracts featuring new clinical and preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando from April 14-19, 2023. The broad range of data being presented at this year’s meeting includes research from Seagen’s approved medicines, as well as data from early-stage clinical, preclinical, and discovery research programs.